Erratum  by unknown
We used RFA to eliminate the hepatic metastatic lesion
instead of hepatectomy. Although complete remission was
achieved, stage IVb thymoma may recur in the future. The
damage to normal liver parenchyma is minimal by RFA
treatment and repeated applications of RFA should be toler-
able if future recurrences appear in the liver.
In patients without preoperative MG, a small propor-
tion develop MG after complete removal of thymoma with
the rare incidences ranging 0.97 to 3.3%.7 Kondo et al.
showed that the frequency of postoperative MG is higher
in patients who have undergone thymectomy and extended
thymectomy (0.7–3.9%) than in patients who have under-
gone selective tumor resection (0.0 –2.8%), suggesting that
complete resection of the thymus gland does not prevent
postoperative MG. On the other hand, they showed that the
improvement rate of postoperative MG treated with anti-
cholinesterase compounds and/or steroids was almost
equal to or better than MG with preresected thymoma and
MG without thymoma. In addition, the prognosis is rela-
tively favorable in thymoma treated with total thymec-
tomy. This implies that thymectomy or extended thymec-
tomy is recommended over simple tumor resection, even
though thymectomy is associated with the frequency of
postoperative MG.7–9 Because it is widely accepted that at
least 1 year is needed for apparent improvement of MG by
thymectomy, MG symptoms in such patients may improve
after months or years from extended thymectomy.10 Fur-
thermore, careful follow-up of both thymoma and MG
should be done in these patients.
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ERRATUM
The Journal of Thoracic Oncology regrets an error in the article, “HOXB2 as a novel prognostic indicator for stage I lung
adenocarcinoma” in the September issue of J. Thorac. Oncol. (vol. 2, number 9, 2007). Yuichi Ishikawa, MD, PhD, was
not listed.
The author listing should have appeared as:
Kentaro Inamura, MD, PhD, Yuki Togashi, MPharm, Michiyo Okui, PhD, Hironori Ninomiya, MD, Miyako Hiramatsu,
MD, Yukitoshi Satoh, MD, PhD, Sakae Okumura, MD, Ken Nakagawa, MD, Takashi Shimoji, MD, PhD, Tetsuo Noda,
MD, PhD, and Yuichi Ishikawa, MD, PhD.
The affiliation printed for Tetsuo Noda was also wrong. Dr. Noda belongs to Genome Center, Japanese Foundation for
Cancer Research (JFCR). The last author, Yuichi Ishikawa, belongs to the Department of Pathology, The Cancer Institute.
We regret any confusion or inconvenience this may have caused, and have corrected the articles as published on jto.org.
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